Hockessin, DE, United States of America

Christine M Tarby

This inventor holds 21 USPTO granted patents and 10 published patent applications and 5 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bristol-Myers Squibb Compnay, Innate Tumor Immunity, Inc., Elan Pharmaceuticals, Inc.. Active years: 2002-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christine M Tarby. Retrieved from https://idiyas.com/inventor/christine-m-tarby

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 

% Patents Active = 85.7

 

Average Co-Inventor Count = 4.8

ph-index = 6

Forward Citations = 161(Granted Patents)


Location History:

  • Wilmington, DE (US) (2002)
  • Cardiff, CA (US) (2004)
  • Hockessin, DE (US) (2002 - 2009)
  • Lawrenceville, NJ (US) (2015 - 2024)

Company Filing History:


Years Active: 2002-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
TLR7 Agonists
NLRP3 Modulators
HIV Reverse Transcriptase Inhibitors
Kinase Inhibitors
Leukocyte Adhesion Inhibitors
Cyclic Amine Derivatives
Tricyclic Compounds
Uracil Derivatives
Diarylalkyl Cyclic Diamine
Imidazotriazinecarbonitriles
Chemokine Receptor Antagonists
Pyrimidine Compounds
21 patents (USPTO):Explore Patents

Title: Celebrating the Innovations of Christine M. Tarby

Introduction

Christine M. Tarby, an accomplished inventor based in Hockessin, DE, has made significant contributions to the field of pharmaceuticals with a total of 15 patents to her name. Her inventive work primarily focuses on developing novel compounds that target critical pathways in cancer treatment and other proliferative disorders.

Latest Patents

Among her latest patents, Christine has developed 1H-pyrazolo[4,3-d]pyrimidine compounds that act as agonists for the Toll-like receptor 7 (TLR7). These compounds hold potential for use in cancer treatment, especially when combined with anti-cancer immunotherapy agents or as a vaccine adjuvant. Additionally, she has introduced NLRP3 modulators, which provide innovative compounds that may be used as medicaments for the treatment of proliferative disorders, such as cancer.

Career Highlights

Christine's career has been marked by her association with prestigious organizations, notably Bristol-Myers Squibb Company. During her tenure, she contributed to groundbreaking research and development initiatives aimed at improving patient outcomes through innovative therapies.

Collaborations

Throughout her career, Christine has had the privilege of working alongside esteemed colleagues, such as Wilna J. Moree and Tatsuki Shiota. These collaborations have fostered an environment of creativity and shared expertise, leading to significant advancements in their respective fields.

Conclusion

Christine M. Tarby's dedication to innovation in the pharmaceutical industry is evident through her extensive patent portfolio and collaborations with notable professionals. Her work not only contributes to scientific knowledge but also holds promise for enhancing treatment options for patients, especially in the fight against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…